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Toll-like receptors (TLRs) are a class of conserved receptors that recognize pathogen-associated molecular patterns (PAMPs)
present in microbes. In humans, at least ten TLRs have been identiﬁed, and their recognition targets range from bacterial
endotoxins to lipopeptides, DNA, dsRNA, ssRNA, fungal products, and several host factors. Of dermatological interest, these
receptors are expressed on several skin cells including keratinocytes, melanocytes, and Langerhans cells. TLRs are essential in
identifying microbial products and are known to link the innate and adaptive immune systems. Over the years, there have been
signiﬁcant advances in our understanding of TLRs in skin inﬂammation, cutaneous malignancies, and defence mechanisms. In
this paper, we will describe the association between TLRs and various skin pathologies and discuss proposed TLR therapeutics.
1.Introduction
T o l lr e c e p t o r sw e r eﬁ r s td i s c o v e r e di nDrosophila where they
are involved in embryogenesis [1]. They were later shown to
assist in innate immunity where their activation resulted in
the production of antimicrobial peptides. Thus, structurally
similar receptors found in other species were named toll-
like receptors (TLRs) [1, 2]. In mammals, TLRs represent a
familyofpatternrecognitionreceptors(PRRs)thatrecognize
distinct, conserved microbial components and permit cells
to recognize self from nonself in immune activation [1,
3]. The TLR family represents a known group of at least
10 human transmembrane proteins which are essential for
innate immunity [4] .I m m u n ec e l l ss u c ha sm o n o c y t e s ,
macrophages, dendritic cells, granulocytes, and nonimmune
cells like keratinocytes express TLRs. Predictably, TLRs are
mostly found on cells that initiate the primary immune
response. TLRs detect a variety of PAMPs which include
Lipopolysaccharide (TLR 4), double-stranded (DS) RNA
(TLR 3), and single-stranded (SS) RNA (TLR 7) [5, 6].
These receptors are located on the cell surface, the endocytic
vesicle membrane, or intracellular organelles [6]. TLRs have
an ectodomain composed of leucine-rich repeats (LRRs)
that may bind directly to ligands [2]. Alternately, acces-
sory molecules may also be involved in ligand binding in
addition to a cytoplasmic toll/interleukin-1 (IL-1) receptor
(TIR) domain, which interacts with TIR-domain-containing
adaptor molecules [6]. In the case of human TLR 4, two
accessory molecules CD14 and MD2 are essential for LPS
recognition [2, 7, 8]. TLRs have the ability to initiate a
rapid and potent response upon ligand engagement. While
TLRs are single-membrane spanning noncatalytic receptors;
diﬀerent TLRs are able to pair up with each other to expand
their range of recognition targets. For instance, TLR 1 and
2 pair up and sense peptidoglycans. While most TLRs signal
through the Myd88 pathway (Myeloid diﬀerentiation factor-
88), TLR 3 and 4 utilize the TRIF pathway (TIR domain-
containing adapter protein that induces IFN-β), and TRAF
6 (TNF receptor-associated factor 6) was found to be the
additional transducer for TLR 7 and 9 [9, 10]. Ensuing these
signalling intermediates, TLRs eventually trigger nuclear fac-
tor kappa-light-chain-enhancer of activated B cells-(NF-κB)
dependentandinterferonregulatoryfactor(IRF-)dependent
activationevents[9].Activationofthesetranscriptionfactors
results in induction of immune and inﬂammatory genes,
namely, tumor necrosis factor alpha (TNF-α)a n dt y p e
I interferons (IFNs) [9]. At these events, TLR-mediated
activation is quite similar to that of another important
inﬂammatory cytokine receptor, interleukin-1 receptor (IL-
1R). TLRs and IL-1R share the Myd88 adaptor molecule2 Mediators of Inﬂammation
and promote the production of proinﬂammatory cytokines
such as leukotrienes (LTs), prostaglandins, and chemokines
[4]. Once activated by TLRs, immune cells initiate phago-
cytosis/killing of pathogens, cytokine, and chemokine pro-
duction, leukocyte activation, and antigen presentation to
T cells, thereby, initiating an adaptive immune response.
An in-depth insight into diﬀerent TLRs and their associated
characteristics such as ligands, cytokines induction proﬁle
and functions have been previously explained by others
[11]. TLRs can modulate adaptive response with respect
to Th1 and Th2 as reported in study, by Medzhitov et al.
[2, 12]. The study found that the mice lacking Myd88 were
defective in giving rise to antigen-speciﬁc Th1 T helper
cells but could initiate a normal Th2 response. All TLR
ligands trigger Th1 response which seem essential in defence
against microbial antigens that are viral, bacterial, and
fungal in nature, in contrast to speciﬁc interaction against
antigens such as helminths that require a Th2 response
[2].
The skin is the ﬁrst line of defence against a variety
of physical and biological assaults. It shields the body
from harmful chemicals, physical trauma, and ultraviolet
(UV) radiation. In addition, it is essential in maintaining
temperature and homeostasis and in our sensing of the
environment. The skin has evolved into a complicated,
yet tightly regulated system appropriate for the complex
functionalities associated within it. The outermost layer of
the skin is the epidermis and is composed of four main
types of cells: keratinocytes, Langerhans cells, melanocytes,
and Merkel cells (Figure 1(a)). Keratinocytes are capable
of proliferating and maintaining the outer layer which is
composed of a stratiﬁed epithelial zone and a water resistant
layer of lipids on the outmost surface. The melanocytes
residing in the skin provide the melanin pigment that is
essential for protection against UV radiation. Interspersed
between keratinocytes and melanocytes are the Langerhans
cells (which function as cutaneous antigen presenting cells
(APCs)) and intraepithelial T lymphocytes. Merkel cells are
oval sensory cells found in the skin. They play a role in
light touch discrimination and may have a neuroendocrine
function. The epidermis is anchored to the dermis below via
connective tissues. The dermis is rich in blood vessels, nerves
and has abundant ﬁbroblasts, dendritic cells, macrophages,
and lymphocytes.
The repertoire of TLRs found on each of these three
epidermal cell types varies (Figure 1(a)). Even though the
precise role against pathogens is poorly understood, in gen-
eral, TLRs in the skin respond to their ligands by activating
NF-κB and producing cytokines [13]. Keratinocytes are
r e p o r t e dt oe x p r e s sT L R s1 ,2 ,3 ,5 ,9 ,a n d1 0[ 14–21]; the
evidence supporting TLR 4 expression in keratinocytes is
conﬂicting [14, 18–20]( Figure 1(b)). As an example of TLR
2 engagement, human keratinocytes mainly signal through
TLR 2 once activated with Staphylococcus aureus (S. aureus)
or Candida albicans [15, 20]. Keratinocytes, treated with S.
aureus, transcribe NF-κB controlled genes (cyclooxygenase-
2, nitric oxide synthetase, and IL-8) and produce enhanced
levels of IL-8, nitric oxide, and chemokines [15]. Ligands
for TLR 2, 3, and 5 stimulate production of matrix
metalloproteases (MMPs) 1 and 9, along with activation of
the NF-κBp a t h w a y[ 22]. The expression of these cytokines is
needed for proper recruitment, inﬂammation, and damaged
tissue remodelling [22]. Translocation of NF-κB and the
associated events permits keratinocytes to stimulate den-
dritic cell maturation and enhance antigen presentation
[23]. Activated keratinocytes are also important epidermal
cytokine producers which mobilize leukocytes, signal other
cutaneous cells and attract neutrophil granulocytes and pro-
fessional killer cells [20]. Langerhans cells express signiﬁcant
levels of TLRs 2, 3, 4, 8, and 10 and low levels of TLRs 1,
5, 6, 7, and 9 [24]( Figure 1(c)). DS RNA, present in some
viruses, induces a particularly robust response in Langerhans
cells, implicating its role in anti-viral immunity via TLR
3[ 25]. Additionally, Langerhans cells can be activated
indirectly by activated myeloid derived dendritic cells and
keratinocytes (Figure 1(d)). For example, they were found
to mature and initiate a Th1 response in the presence of
keratinocytes that secreted IFNα and IL-18 upon exposure to
antigen, such as DS RNA or polyinosinic-polycytidylic acid
(poly IC) stimulation [23]. Lastly, human melanocytes have
been shown to express TLRs 2, 3, 4, 7, 9 (at the protein
level), and respond to TLR 4 ligands by MMP induction
[25, 26]( Figure 1(e)). When stimulated by TLR ligands,
human melanocytes can: (1) release IL-6 and IL-8 cytokines,
(2) enhance chemokine (CCL2, CCL3, and CCL5) mRNA
production, (3) upregulate phosphorylated IκBα (nuclear
factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha), and (4) promote translocation of NF-
κBp65 to the nucleus [25].
TLRs are increasingly being implicated in many immune
and inﬂammatory diseases, cancer, and wound healing. For
example, TLR 2, TLR 4, TLR 5, and TLR 7 are implicated
in tumor metastasis, sepsis, radioprotection, and systemic
lupus erythematosus, respectively [83]. Wound healing
was found to be aﬀected in Myd88−/− mice suggesting a
synergistic role for TLRs in this process [84]. That study
revealed interplay between purinogenic receptor signalling
and Myd88−/− pathways but did not explore IL-1 cytokine
proﬁle. The involvement of Myd88 hints at an important
function of associated TLRs, especially TLR 2 and 4, in slain
tissue remodelling. Lai et al. revealed a novel mechanism
by which bacterial products modulate local inﬂammation
in a TLR 2-dependent manner [85]. Understanding TLR
signalling pathways, their structural interaction with lig-
ands, and inhibition strategies may provide avenues for
potential clinical intervention [83]. In order to clinically
manipulate TLRs, pharmacologics should alter TLR activity
through receptor antagonists, receptor agonists and signal
transduction inhibitors. Moreover, neutralizing antibodies,
monotherapies and adjuvancy may also be used to target
TLRs. E5564 (Eritoran) is a good example of a current
pharmacological (TLR 4 antagonist) agent which is being
clinicallytestedfortreatmentofGram-negativeendotoxemia
and sepsis [83]. TLR-mediated activation or dysfunction
has been attributed to exacerbation of diﬀerent diseases.
The manipulation of speciﬁc TLRs may therefore lead
to the development of novel therapies for autoimmunity,
cancer, and inﬂammatory disease. Next we will discuss howMediators of Inﬂammation 3
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Figure 1: (a) Cross-section of epidermis. Keratinocytes are present throughout the skin; other epidermal cell types include Langerhans
cells, melanocytes, and merkel cells. (b) Keratinocytes express TLRs 1, 2, 3, 4, 5, 9, and 10. MD2: TLR4-associated molecule; MyD88:
myeloid diﬀerentiation factor 88; NF-κB: nuclear factor-κB; TRAF-6: TNF receptor-associated factor-6; TRIF: TIR domain-containing
adapter protein that induces IFN-β. (c) Langerhans cells express high levels of TLRs 2, 3, 4, 8, and 10. but express low levels of TLRs 1, 5,
6, 7, and 9. (d) Upon activation, myeloid-derived dendritic cells and to a lesser extent keratinocytes release IFNα and IL-18 which stimulate
Langerhans cell maturation. With antigen stimulation the Langerhans cell induces a Th1 response. (e) In response to TLRs 2, 3, 4, 7, and 9
melanocytes initiate proinﬂammatory events via the illustrated pathways.
TLRs have been linked to dermatological disease and their
proposed therapeutic role.
2.TLRsinDermatologicDisease
2.1. Atopic Dermatitis and Allergic Contact Dermatitis.
Atopic dermatitis (AD), which aﬀects up to 20% of the
pediatric population, is a chronic inﬂammatory skin disease
characterized by pruritus, eczematous lesions, xerosis, and
licheniﬁcation. It often forms part of the atopic triad
composed of allergic rhinitis, asthma, and eczema [86, 87].
Patients suﬀering from AD have greater susceptibility to
bacterial, viral, and fungal infections; in fact, S. aureus has
been associated with its ﬂares and severity [71, 88, 89]. In
addition to S. aureus, the best characterized infectious agent
of AD, strains of Candida species have a strong ability to
colonizeatopicskin,andvirusessuchasherpessimplexvirus
can aggravate the infection and exacerbate the disease [90].
These pathogens express microbial products that stimulate
TLR 1, 2, 6, and 9. Recent studies show a strong association
between TLR 2 and the symptoms of severe AD in some
populations [29, 30]. The presence of a single nucleotide
polymorphism (SNP) R753Q in the TLR 2 allele has been
reported to be associated in patients with severe AD and
whoseskinwaspronetoS.aureusinfection[11,91].Therole
of R753Q in AD has been conﬁrmed in the cytokine-based
proﬁling of patients where stimulation of TLR 2 induced
altered production of IL-6 and IL-12 [92]. Conversely, a
study in a German population found no signiﬁcant eﬀect
of TLR 2 and 4 polymorphisms in relation to susceptibility
for AD [93]. On the other hand, polymorphism C-1237T
in the TLR 9 gene has been attributed as the cause for
impairment of immunity in some cases of AD [31]. Taken
together, these studies suggest that there is a defect in TLR
2/9. These defects may be genetic (dysfunctional proteins)
or functional (attenuation of regulatory pathways) [31, 32,
87]. This defective recognition of pathogenic antigens by
TLRs renders greater susceptibility of AD lesions to various
bacterial and viral infections [1]. However, there has been
no signiﬁcant correlation between TLRs 1 and 6 (recognize
peptidoglycans, and lipoproteins resp.) and AD [30, 94,
95]. Although correlation between TLRs 2, 9 and AD has
been reported, another study using monocyte-derived DCs6 Mediators of Inﬂammation
found no relation between polymorphism, function of TLR
2-4 with respect to AD [96]. Allergic contact dermatitis
(ACD), another eczematous process, is a type IV delayed
hypersensitivity reaction seen in the skin typically after
sensitization by haptens [97]. The bacterial infections and
haptens binding with self-proteins in the skin leads to
activation of DCs stimulating a speciﬁc autoreactive CD8
response against the epidermis in a TLRs 2-, 4- and 9-
dependent fashion [32, 98, 99].
In the case of AD, defective epithelial barrier func-
tion, receptor expression, and signalling pathways (altered
cytokine production) play a role in disease progression [94,
100–102]. AD and ACD are routinely treated with emollients
and topical steroids (for skin ﬂares). Topical calcineurin
inhibitors (TCIs), such as pimecrolimus and tacrolimus, are
used to treat AD by modulating T cell activation [102–
104]. Pimecrolimus is capable of enhancing the ability of
keratinocytes to inhibit pathogen growth. Although pime-
crolimus and tacrolimus, have been shown to eﬀectively
reduce the symptoms observed compared to placebos, the
long-term eﬀects need to be studied in more detail before
declaring the treatments safe [102, 103]. Unfortunately TCIs
received a black box warning from the FDA for possible links
to carcinogenicity.
Another feasible option for the treatment of severe
cases of AD is phototherapy. In patients with acute ﬂares,
ultraviolet A (UVA), ultraviolet B (UVB), or a combination
of UVA and UVB therapy may be administered, often
with concomitant topical corticosteroids, with a reasonable
amount of success [102]. Phototherapy with narrow and
broad band UV radiation is noted to be eﬀective in treating
AD as radiation interferes with the immune function and
inﬂammatory process of the local milieu [105–107]. This
is relevant to TLRs in the light of ﬁndings that TLR 2-
and 4 mediated production of cytokines plays a role in
immunosuppression along with T regulatory cells [50].
2.1.1. Psoriasis. Psoriasis is a common, chronic, relapsing,
inﬂammatory skin disorder with a strong genetic basis.
Chronic plaque psoriasis is the most common form of the
disease, but other manifestations include guttate, inverse,
pustular, erythrodermic, and psoriatic arthritis. Psoriasis is
characterized by epidermal hyperproliferation (acanthosis),
marked hyperkeratosis with parakeratosis (abnormal mat-
uration), loss of the granular layer, vascular dilatation, and
inﬂammatory cell inﬁltration. Abnormalities in biochemical,
inﬂammatory, and immunological markers are commonly
identiﬁed. In the skin of psoriasis patients, there is increased
antigen presentation, T cell proliferation, Th1 and Th17
cytokine production, and angiogenesis. Inappropriate recog-
nition of self-nucleic acids in addition to type I IFNs (IFN-
α/β) production by plasmacytoid DCs (pDCs) can lead to
psoriasis [108]. pDCs are an important cell population in
this condition, because they are 16% of the total dermal
inﬁltrate in psoriatic skin lesions whereas they are rare in
atopic dermatitis and nonexistent in normal skin [108]. As
an example, mechanical injury towards prepsoriatic skin
promotes the release of cationic antimicrobial peptide (LL37)
by keratinocytes [61]. The overexpressed LL37 binds to
extracellularself-DNAandformsaggregatesthatenterpDCs,
activate TLR 9, and trigger type I IFN production. Type I
IFNs produced by pDCs support myeloid dendritic cell mat-
uration and eventual autoreactive T cell activation leading
to psoriatic skin lesions, in a self-sustaining feedback loop.
Concurrently, Th17 cells produce IL-22 and IL-17 which
stimulate epidermal hyperplasia and neutrophil recruitment
and further enhance inﬂammation. IFN-α (type 1 IFN) in
addition to ssRNA (a simulator of viral infection) also acts
as an important trigger for DC activation in psoriasis [109].
Another important growth factor expressed during psoriasis
is TGF-α, which upregulates TLRs 5 and 9 expression
and function in human keratinocytes [110]. Heat shock
proteins (i.e., HSP60) are suspected immunogenic proteins
that are heavily expressed by epidermal keratinocytes of
guttate and plaque psoriasis in comparison to normal skin
[111]. HSP60 may subsequently trigger TLR 2 and TLR 4
to stimulate innate and adaptive immunity which develops
and/or aggravates psoriasis. The A domain of ﬁbronectin
(keratinocyte derived) may act on the TLR 4 pathway in
APCs (Langerhans cells) to cause maturation, TNF-α and
IL-12 secretion, and antigen presentation to autoreactive
T cells [112]. Interestingly, anti-keratin 16 antibodies are
highly concentrated in the serum of psoriasis patients and
may be involved in chronic inﬂammation. Keratinocytes
incubatedwithmouseantikeratin16monoclonal,antibodies
have increased levels of TLR 2, TLR 4, involucrin, and NF-
κB nascent polypeptide-associated complex mRNA [113].
As implied earlier, psoriasis is a T cell-mediated disease
caused in part by activated T cells interacting with antigen-
presenting cells (APCs) in addition to IFN-γ,I L - 1 ,a n d
TNF-α eﬀects [114, 115]. T cells are distinctly compart-
mentalized in the diﬀerent skin layers in psoriatic lesions
[116]. CD4+/Th1 T cells are, for example, located in the
upper dermis unlike CD8+/Th1 T cells that are found in
the epidermis [117]. T cells are functionally important since
cyclosporine A (an immunosuppressant which binds the
cyclophilins of T lymphocytes), as well as CTLAﬂg, anti-
CD4 antibodies, DAB389IL-2, and alefacept (all T cell-
based immunomodulators) are highly eﬀective therapies
for psoriasis [118–122]. Further support is provided in
rare instances of psoriasis transfer to recipients of bone
marrowtransplantsfromdonorswiththediseaseandsimilar
episodes in xenotransplantation models [123, 124].
In regard to TLR expression, keratinocytes in the epi-
dermis constitutively express TLR 1, 2, and 5. In psoriasis
lesions, the expression of TLR 1 and TLR 2 on keratinocytes
isfurtherupregulated[62].Keratinocytesinhumanpsoriatic
skin, activated by TLR 2, 3, and 4 ligands exhibited NF-κB
nuclear translocation and release of TNF-α and IL-8 [63].
An immunohistochemistry-based proﬁle of psoriatic skin
also demonstrates the overexpression of TLR 2 in epidermal
and dermal DCs and the enhanced TLR 2 expression in
basal layer keratinocytes. It enhanced TLR 4 expression in
epidermal and dermal DCs, in addition to accumulation of
CD14-positive macrophages [125]. TLRs 7 and 8 signalling
have also been implicated in psoriatic exacerbations [112]
since imiquimod (a TLR 7/8 agonist) aggravates pathological
symptoms.Mediators of Inﬂammation 7
Topicalimmunosuppressivetherapiessuchastopicalcor-
ticosteroids(i.e.,budesonide),pimecrolimus,andtacrolimus
are currently used for treating inﬂammatory skin diseases
like atopic dermatitis. They function by suppressing IL-8
and TNF-α mRNA expression and either induce (budes-
onide) or suppress (tacrolimus) TLR 2 mRNA expression in
human keratinocytes [126, 127]. Although further studies
are required, it appears that the clinical use of systemic
and topical retinoids helps to control psoriatic inﬂammation
through TLR 2 inhibition [50]. Monomethyl fumarate
(fumaric acid ester) is also used as an immunotherapy
for psoriasis; markedly, it interferes with LPS signalling
through TLR 4 in dendritic cells, inhibits NF-κB activation,
decreases IL-12p70 and IL-10 production, and modulates
monocytes-derived DC polarization [128]. Furthermore,
the TLR 7/8 agonist imiquimod, which was considered a
potential therapy, resulted in exacerbated psoriatic lesions,
increased DCs inﬁltration, and elevated IFN-γ. Another
example of potential treatment for psoriasis is the use of
anti-inﬂammatory pharmacologics such as salicylates (as
well as other nonsteroidal anti-inﬂammatory drugs) and
parthenolide, which block IkappaB kinase (IKK-1 and IKK-
2) activity [123]. IKK-1 and IKK-2 are part of the TLR
signalling cascade [129]. Although advances are being made
and compounds are being clinically tested to target the
common signaling pathways of the TLR superfamily to
prevent p38 mitogen-activated protein, NF-κBa c t i v i t y ,a n d
TNF production, caution must be exercised when testing
these TLR therapies [129].
2.1.2. Acne Vulgaris. Sebaceous glands are a holocrine gland
that secretes sebum [130] formed by the breakdown of
glandular cells. Full blown acne manifests in the piloseba-
ceous follicle and is attributed to increased sebum excretion,
sebumlipidalteration,androgenandneuropeptideactivities,
follicular hyperkeratinization, dsyregulation of cutaneous
steroidogenesis, and growth of anaerobic, gram positive Pro-
pionibacterium acne (P. acnes) [131, 132]. P. acnes helps sus-
tain inﬂammation by TLR-mediated induction of cytokines,
upregulation of adhesion molecules, and chemokine medi-
ated recruitment of immune cells [133]. Immune cells
such as TLR 2 expressing macrophages (perifollicular and
peribulbar) tend to surround pilosebaceous follicles in acne
lesions; subsequent TLR 2 triggering due to P. acnes results
in IL-6, IL-8, and IL-12 cytokine production [4]. The pro-
inﬂammatory response in acne lesions seems to be largely
initiated by TLR 2 since the lipid components from the cell
wall of P. acnes a l s ot r i g g e rT L R2a c t i v a t i o ni nm o n o c y t e s
[4]; almost all of the TLR 2-expressing cells in acne
lesions are derived from CD14 monocytes, suggesting active
monocyte recruitment. Monocytes are, in turn, stimulated
to produce TNF-α, IL-12, IL 1-β, and IL-8 [4, 133], which
are all major pro-inﬂammatory cytokines/chemoattractants.
Consequently, neutrophils and lymphocytes are attracted
to the follicle and exaggerate the observed inﬂammation.
Acne inﬂammation may also develop because P. acnes
stimulates the expression of TLR 2, 4 and CD14 in human
keratinocytes [27]. Keratinocytes and sebocytes, located near
the pilosebaceous unit, may be capable of detecting either
pathogens or abnormal lipids [27]. Human SZ95 sebocytes,
in particular, express innate immune molecules such as
TLR 2, TLR 4, IL-1β, IL-6, IL-8 [27], CD1d, and CD14
[131]. As a result of TLR stimulation due to P. acnes,p r o -
inﬂammatory cytokines, chemokines, antimicrobial lipids
[132] and antimicrobial peptides (i.e., cathelicidin, defensin-
1, defensin-2, and psoriasin) [134–137], and human B-
defensin-2 are produced by these cells [138].
In acne vulgaris, TLR 2 activation can induce robust
inﬂammation as well as cellular apoptosis and tissue injury
[4, 28]. Pharmacological agents have been designed to target
inﬂammation through downregulation of TLR expression
and function. Retinoids (a class of vitamin A-derived com-
pounds) bind retinoic acid receptors (RAR) and modulate
keratinocyte maturation [139–141]. When primary human
monocytes are treated with ATRA (all-trans retinoic acid),
TLR 2 and CD14 are downregulated without any change in
expression of TLR 1 and 4 [142]. Further, ATRA pre- and
cotreatment of monocytes inhibited the ability of TLR 1/2
ligands to trigger cytokine production [142]. In response
to P. acnes, ATRA-treated monocytes result in cytokine
downregulation of IL-12p40, TNF-α, and IL-6 [142]. Other
antiacneic drugs such as retinoic acid, ZNSO4, doxycycline,
nicotinamide, nitroimidazole, retinol, and isotretinoin pre-
vent O2
• production, IL-8 release and keratinocyte apop-
tosis [143]. Nicotinamide, through interaction with TLR 2
on primary keratinocytes and immortalized HaCaT cells,
signiﬁcantly depresses IL-8 production (both at mRNA and
protein levels) in a dose-dependent manner [144]. It appears
that nicotinamide’s downregulation of IL-8 is accomplished
at the level of transcription by reducing promoter activ-
ity. It also inhibits IκB degradation (reduced NFκB) and
phosphorylation of Jun N-terminal (JNK) MAP kinases and
extracellular receptor kinases (ERK) [144]. Current acne
therapies exert their eﬀects, at least in part, via TLRs, and
newly developing TLR therapies show great potential.
2.2. Nonmelanoma Skin Cancers. Non-melanoma skin can-
cer (NMSC) is the most common form of cancer worldwide.
The two major types of NMSC are basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC). Risk factors
for the development of NMSC include exposure to high
doses of UV and ionizing radiation, chemical carcinogens,
immunosuppression, oncogenic viral strains, and genetic
predisposition.
BCCs, typically occur in areas of chronic sun exposure
are slow growing and rarely metastatize [145–147]. Current
therapies consist of surgical removal, radiotherapy, photody-
namic therapy, cryotherapy, and intralesional injections of
IFN-α [148]. Imiquimod has been administered successfully
as a topical immune modulator which induces production
of IFN-α and IL-2, leading to a heightened immune response
[33,145,146].Theeﬀectisthereforeexpectedtobemediated
by TLR 7/8. Topical application of 5% imiquimod has
demonstrated eﬃcacy in several clinical trials [33–35, 145,
149–151]. Stary et al. reported observations where topical
imiquimod treatment leads to induction of a speciﬁc subset
of DCs which mediated destruction of BCC lesions [36,
37]. CpG ODNs are composed of repeating unmethylated8 Mediators of Inﬂammation
CG regions causing them to resemble bacterial DNA. PF-
3512676 (a synthetic CpG ODN) is also considered safe and
eﬀective in treating BCC [38], which presumably targets
TLR 9.
The prevalence of SCC is second only to that of BCC.
It is found more commonly in elderly Caucasian men with
signiﬁcant cumulative UV damage [147, 152–154]. Unlike
BCCs, SCCs have higher rates of metastasis and tend to be
more aggressive in immunosuppressed patients [152]. SCCs
are typically treated by surgery, radiation therapy and other
chemotherapeutic modalities [154]. Combination therapy
consisting of immunosuppressive agents (methotrexate,
bleomycin supplemented with 5-bromouracil) did not yield
tangible results [155]. A similar method using interferon
instead of bromouracil was reported to be much more
eﬀective [154, 156]. As in the case of many skin diseases,
imiquimod has been tested for SCC mitigation. TLR 7 and
8 have been manipulated to activate the pro-inﬂammatory
machinery against SCC [154]. The modulation of IL-1, IL-
6, IL-8, and IL-12 along with promotion of a Th1 response
promotes antitumor and antiviral behaviour [154]. Several
studies have shown imiquimod to be a viable option to test
for eﬃcacy in treatment of SCC [68–70].
2.3. Melanoma. Melanoma is a malignant tumor of
melanocyteswhichcausesthemajorityofskincancer-related
deaths worldwide [58, 157, 158]. Exposure to UV radiation
is the main risk factor for the disease [58, 157, 159].
Melanocytes have the ability to help tumor progression
in melanoma by responding to hyaluronic acid fragments
through TLR 4 by inducing MMP and cytokine production
[59]. Although melanocytes have been shown to express
other TLRs [25], TLR 9 has been targeted for modulating
immune response. A study on a murine lymphoma model
which revealed the potential of CpG ODNs in enhancing
immunogenicity of the tumours resulted in exploitation of
TLR 9 ligands for melanoma [60, 160].
Many TLR ligands are considered good adjuvant candi-
dates as they can activate dendritic cells. Diﬀerent TLR 9
agonistsarenowincludedinvaccineformulationsforhuman
trials. In earlier studies, a vaccine with antigenic peptide
and IFA (incomplete Freund’s adjuvant) was reported to
induce a weak T cell response. On the contrary, studies with
CpG ODNs produced a strong immune response against
the Hepatitis B virus [161]. In clinical studies using CpG
7909 (a variant of CpG ODNs) in combination with a
melanoma peptide, the vaccine resulted in 10-fold greater
speciﬁc CD8 T cells compared to peptide alone [60, 161,
162].RecentlyavariantofCpG7909namedPF-3512676was
used[163]in aphaseIIclinicaltrialwhichyielded promising
results and had a moderate safety proﬁle but displayed
some very rare adverse events. In all, TLR 9 targeting
appears to be a viable option in melanoma treatment [164].
In addition, imiquimod (a TLR 7 agonist) was used to
harness the potential TLR 7-based treatment for melanoma.
Imiquimod is eﬀective in both activating dendritic cells and
producing tumor-speciﬁc cytotoxic T cells that arrest disease
progression [165].
2.4. Therapeutic Drugs
2.4.1. Imidazoquinolinamines—Immune Modulators. Imida-
zoquinoline compounds (ICs) have similar structure to
nucleosides found in all living organisms. They were initially
produced and tested as antiallergic drugs in rats, and were
reported to be reasonably eﬀective [166]. After extensive
studies, the potential of ICs to stimulate secretion of pro-
inﬂammatory cytokines was ﬁnally discovered [167, 168].
Toll like receptor 7/8 directs a cascade of events which
leads to the release of speciﬁc cytokines [169]. Imiquimod
and resiquimod are two compounds that are eﬃcient at
activating the immune system [170]. Both compounds
induce secretion of IFN-α,T N F - α, IL-6, and other pro-
inﬂammatory cytokines from APCs such as resident B cells,
pDCs, and monocytes [170–173]. They achieve this response
by activating TLR pathways and promoting nuclear trans-
migration of transcription factors like NFκBa n da c t i v a t o r
protein 1 (AP1). Imiquimod, the more extensively studied
analogue, is known to enhance apoptotic pathways in cancer
cells. It binds to the high aﬃnity adenosine receptors and
suppresses its ability to regulate negative feedback [168].
Resiquimod, a chemically related compound, exhibited 100-
fold greater ability to stimulate apoptosis in preliminary
studies [170]. Unfortunately, unlike imiquimod, resiquimod
hasnotbeenstudiedextensively[50].Atthetimeoftheirdis-
covery, imidazoquinolines were hypothesized to eﬀectively
treat Kaposi’s sarcoma, human papillomavirus (HPV) and
other infections [170]. Initially generated to be an antiviral
agent, it was quickly utilized for its expanding therapeutic
potential. Imiquimod was one of the ﬁrst of such analogues
to be authorized for treatment of genital warts caused by
HPV [6, 26]. Imiquimod has also been used to activate
the immune system in many diseases like actinic keratoses
[50], BCC [35, 149–151], SCC [70, 154], and melanoma
[58,60,165,174–176].Twootherimmunomodulatorswhich
function through TLR 7, loxoribine, and bropirimine have
also been used [6]. Loxoribine, a guanosine ribonucleoside,
enhances production of IFN and activates NK cells and
B cells [50, 177, 178]. Bropirimine, an aryl pyrimidinone
class of antineoplastic compounds, has a similar eﬀect to
loxoribine and is currently in clinical studies for treatment
of carcinomas [50, 179].
2.4.2. Calcineurin Inhibitors—Immune Suppressors. Cal-
cineurin inhibitors are potent suppressors of the T cell medi-
ated immune response due to their ability to inactivate the
serine protease calcineurin. This prevents nuclear transloca-
tion of (NFAT nuclear factor of activated T cells), thereby
inhibiting the synthesis of pro-inﬂammatory cytokines in T
cells [104, 171]. Pimecrolimus and tacrolimus are ascomycin
macrolactam derivatives that are categorised as inhibitors
of calcium-dependent phosphatase. In the early stages of
AD, the topical application of 1% pimecrolimus was deemed
more eﬀective than topical steroids [102, 171]. Diﬀerent
formulations of the drug are being tested for eﬃcacy in
psoriasis, vitiligo, and other skin diseases [127, 171, 180].
As previously mentioned, pimecrolimus has been shown
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Table 1: Toll like Receptors in dermatologic disease.
Disease/infection Toll like receptor associated Associated function with the disease References
Acne vulgaris TLR 2, 4, CD14 TLR upregulation with eventual
exacerbation of the disease
[4, 27, 28]
Atopic dermatitis TLR 2, 9 TLR polymorphism leading to
increased susceptibility
[29–32]
Basal cell carcinoma TLR 7, 8, 9 Exacerbation of disease, target for
therapy
[33–38]
Behc ¸et’s
disease-vasculitis
TLR 4, 6
TLR 4 polymorphism leads to
increased susceptibility, diﬀerential
regulation of TLR 6 helps in
progression of disease
[39, 40]
Borreliosis/Lyme
disease
TLR 1/2 (heterodimers),4, 6 TLR upregulation with eventual
exacerbation of the disease
[41, 42]
Candida albicans TLR 2, 4-CD14, 6 TLR function and signalling leads
to disease progression
[43–45]
Cutaneous graft
versus host disease
TLR 4 Exacerbation disease in response to
LPS
[46]
Herpes
simplex/Varicella
zoster
TLR 2, 3, 9
Select TLR 2 polymorphism
associated with disease severity,
TLR 3 and 9 help in viral clearance
[47–49]
Leprosy TLR 1, 2 TLR function and signalling lead to
disease progression
[21, 50–52]
Lichen planus TLR 9 TLR upregulation with eventual
exacerbation of the disease
[53, 54]
Lupus erythematosus TLR 3, 7, 9
TLR 7 upregulation and TLR 3∗,
TLR 9 function helps to create
autoreactive cells
[55–57]
Melanoma TLR 4, 7, 9
TLR 4 exacerbates disease TLR
7,9-targetted for immune
modulation
[25, 58–60]
Psoriasis TLR 1–4, 5, 9 TLRs upregulated and help in
creation of autoreactive T cells
[17, 61–63]
Sarcoidosis TLR 2, 4 TLRs polymorphism associated
with disease severity
[64–66]
Scleroderma TLR 4 TLR function and signalling lead to
disease progression
[67]
Squamous cell
carcinoma
TLR 7, 8 Exacerbation of disease, being
studied to target for therapy∗ [68–70]
Staph. Aureus TLR 2, 6
TLR 2 polymorphism associated
with severity∗, TLR 2/6 function
and signalling lead to disease
progression
[71, 72]
Stevens-Johnson
syndrome/Toxic
epidermal necrolysis
TLR 3 TLR polymorphism linked to
disease severity
[73]
Syphilis TLR 2, 4/5 (heterodimer) TLRs activate the immune system [26, 50, 74]
Vaccinia TLR 2,3, 4
TLRs help in viral clearance but are
targeted by viral products which
suppress host defense
[71, 75, 76]
Verruca and
Molluscum
Contagiosum
TLR 3,7,9
TLR 3, 9 help in immune activation,
TLR 7∗ possible association with
disease exacerbation, proposed
target for therapy
[77–80]
Yersinia spp—the
plague
TLR 2, 4-CD14 Pathogen exploits TLR pathway to
survive
[50, 81, 82]
∗proposed association subject to further investigation.10 Mediators of Inﬂammation
when coadministered with TLR 2/6 ligands [104]. Similar
to pimecrolimus in structure and function, tacrolimus is
utilized for identical purposes, albeit at lower concentrations
(0.03% to 0.1%). Tacrolimus appears safe for administration
at 0.1% for treatment of AD but with certain adverse side
eﬀects, such as burning sensation and pruritus observed in a
small minority [103]. The drug is under trial for treatment
of other diseases such as seborrheic and contact dermatitis,
systemic lupus erythematosus, and bullous pemphigoid
[171, 180]. Sirolimus or rapamycin is a macrolactam-like
compound which inhibits IL-2 synthesis and cell cycle path-
ways [181]. Sirolimus, if injected along with cyclosporine
A, prevents the progression of UV-mediated skin cancer
[182]. The drug is under consideration in combination with
other drugs for treatment of skin malignancies, hepatocar-
cinomas, lupus, psoriasis, dermatomyositis, graft rejection,
and a genetic disorder, pachyonychia congenital [180, 183–
188].
Table 1 lists a selected group of skin diseases and
the diﬀerent TLRs aﬃliated with each disease. The TLRs
associated can either activate the immune system or promote
disease progression as indicated.
3. Conclusion
Toll like receptors represent a conserved group of receptors
which help the immune system to function properly. Dif-
ferent TLRs are associated with an array of skin diseases
(Table 1). TLR agonists and antagonists have great potential
for the treatment of allergic and inﬂammatory diseases.
More research must discern the relationship between speciﬁc
TLRs and the corresponding disease in order to harness
the therapeutic potential of TLR ligands. Although studies
have proven that TLR agonists like CpG can induce a robust
immune response, the eﬃcacy of the vaccines, optimization
of dosage, long-term eﬀects, and augmentation requires
further study [162, 172].
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